TD Cowen analyst Ritu Baral maintains $Sangamo Therapeutics (SGMO.US)$ with a buy rating.
According to TipRanks data, the analyst has a success rate of 51.0% and a total average return of 15.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Sangamo Therapeutics (SGMO.US)$'s main analysts recently are as follows:
Subsequent to the Q3 report, there is an alignment with the FDA on an accelerated approval pathway. The discussion during the Q3 call was centered on the advancement of the Fabry program, with partnership negotiations reportedly in the advanced stages. There is an anticipation of favorable data by Q3 of 2025, followed by potential FDA approval in 2026, and a deal announcement is expected in the near future.
The firm perceives the establishment of partnerships on the Fabry program and the comprehensive results from the pivotal study as pivotal catalysts. It is believed that the stock's upside will be propelled by proof of concept of the company's wholly owned ZFP transcription factor neurology programs.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
